|drug2247||Non-invasive red LLLT treatment to chest of patient. Wiki||1.00|
There is one clinical trial.
To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.
Description: Change in inflammation of the lungs as measured by O2 saturation levelsMeasure: Inflammation of the lungs - O2 Time: 10 days
Description: Change in inflammation of the lungs as measured by C-Reactive Protein (CRP) TestMeasure: Inflammation of the lungs - CRP Time: 10 days
Description: Change in inflammation of the lungs as measured by IL-6 LevelsMeasure: Inflammation of the lungs - IL6 Time: 10 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports